CAH·Cardinal Health, Inc.
CAH|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $2.94 | - | - |
| Q4'26 | $2.88 | $2.91 | +1.2% |
| Q3'26 | $2.82 | $3.17 | +12.5% |
| Q3'25 | $2.17 | $2.55 | +17.6% |
| Q2'25 | $2.03 | $2.08 | +2.4% |
| Q1'25 | $2.15 | $2.35 | +9.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'27 | $66.7B | - | - |
| Q4'26 | $65.7B | $63.7B | -3.1% |
| Q3'26 | $62.3B | $60.9B | -2.2% |
| Q3'25 | - | $64.0B | - |
| Q2'25 | - | $60.2B | - |
| Q1'25 | - | $54.9B | - |
Market Data
CAH Stock Snapshot
CAH is currently trading at $234.00, giving Cardinal Health, Inc. a market cap of 53.87B and a P/E ratio of 34.6. Today's range spans $232.37–$238.10, with shares opening at $232.51 and moving up $1.64 (0.7%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 41/100.
Over the past year CAH has traded between $145.87 and $258.30 - the current price is +60.4% off the 52-week low and -9.4% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $270.94 (range $235.00–$292.00), implying upside of +15.8%.
Neither bulls nor bears have the upper hand on Cardinal Health, Inc. (CAH) right now. Score: 50/100 (HOLD). Sentiment: neutral (41/100). Price: $234.00 (in the upper portion of its 52-week range). (P/E: 34.6) At 53.87B in Healthcare market cap, the 52-week range of $145.87–$258.30 is the relevant frame - where the stock sits within that range, and whether volume confirms any directional move, matters more than the HOLD label alone.
In neutral phases, large-cap Healthcare names like CAH are often where sector rotation debates play out quietly, at 53.87B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 50/100 (HOLD) and neutral sentiment (41/100) at $234.00 (in the upper portion of its 52-week range) describe a stock that is being considered rather than avoided.
Company Insights: Cardinal Health (CAH)
Cardinal Health’s core distribution model places it in a mildly cyclical niche within healthcare, where demand aligns closely with prescription volume and hospital procurement cycles. The company’s 52‑week low of $137.75 and high of $244.87 illustrate that investor sentiment has been volatile as macro‑driven drug‑pricing negotiations and reimbursement policy shifts unfold. When federal budgets tighten or insurers adjust coverage tiers, the distribution pipeline can compress, nudging the share price toward the lower end of the range. Conversely, periods of heightened healthcare spending, such as post‑pandemic recovery or new drug launches, tend to lift the stock toward the upper 52‑week boundary. Thus, the 52‑week spread serves as a barometer for the broader economic cycle’s impact on Cardinal Health’s revenue streams. The current price sits 38.9% above the 52‑week low, indicating a moderate upside potential if macro conditions improve.
Interest‑rate hikes exert a modest drag on Cardinal Health because the firm’s revenue is anchored in essential medical supplies rather than discretionary consumer goods. Nonetheless, higher borrowing costs can constrain hospital capital budgets, indirectly affecting procurement volumes. The company’s recent 13.6% year‑to‑date return outpaces many peers, suggesting that supply‑chain resilience has mitigated some rate‑related headwinds. Over the past three months, the stock has gained 27.6%, a performance that reflects the resilience of its distribution network amid a tightening monetary environment. However, a sustained rate rise could compress margins if cost‑of‑goods increases outpace pricing power. Monitoring the Fed’s policy trajectory remains essential for assessing future upside or downside risk.
Cardinal Health trades at a forward P/E of 35.6, comfortably below the peer average of 53.0 across Agilent, AbbVie, Abbott, and Align. This valuation discount reflects the company’s stable earnings trajectory and lower growth expectations compared to biotech peers. While the lower P/E offers a margin of safety, it also signals that the market may be pricing in potential margin pressure from supply‑chain integration costs. Relative to peers, Cardinal Health’s revenue growth of 16% year‑over‑year in the latest quarter is modest, yet it aligns with the broader medical‑distribution sector’s steady expansion. The company’s market cap of $55.4 billion positions it as a mid‑cap leader within the healthcare distribution sub‑industry. Investors weighing sector rotation should consider whether the valuation spread will widen or narrow as the industry cycles.
Analyst consensus on Cardinal Health sets a mean target of $252.4, implying roughly 6.8% upside from the current price of $236.4. The high target of $275.0 and low of $215.0 frame a range that reflects divergent views on the company’s integration strategy. With 20 analysts rating the stock as a buy, sentiment remains largely bullish, despite a 71% sentiment score that has recently fallen. The upward earnings beats in the last five quarters bolster confidence that the firm can navigate supply‑chain challenges. However, the 3‑month return of 27.6% has already captured much of the upside, suggesting a potential slowdown if the market revises expectations. Analysts emphasize that the valuation premium will likely compress if margin improvement stalls or if acquisition costs outweigh projected synergies.
Recent headlines spotlight Cardinal Health’s push into home‑care through the acquisition of Strive Medical and AdaptHealth, signaling a strategic shift toward outpatient services. Management’s commitment to supply‑chain resilience is expected to drive cost efficiencies, but integration expenses could temper near‑term earnings. The company’s Q3 2026 results showed a revenue dip of $1.34 billion versus estimates, yet EPS rose to $3.17, underscoring operational leverage. Analysts note that the home‑care mandate could unlock new revenue streams, especially as Medicare and private payers expand coverage for remote monitoring. The firm’s focus on radiopharmaceutical preparation and pharmacy management also positions it to benefit from increasing demand for specialty drugs. Investors should watch Q4 2026 earnings for guidance on whether the revenue dip is a one‑off event or a trend, and assess how supply‑chain improvements translate into margin expansion.
Distribution Stability
Cardinal Health’s nationwide distribution network spans over 20,000 facilities, ensuring consistent product flow even during supply‑chain disruptions.
The company’s dual‑segment structure, Pharmaceutical and Specialty Solutions alongside Global Medical Products, diversifies revenue sources and dampens cyclical swings.
Long‑term contracts with hospitals and pharmacies provide predictable cash flow, anchoring earnings during periods of macro uncertainty.
Margin Outlook
Historical EPS growth of 55% from Q4 2024 to Q3 2026 demonstrates the firm’s ability to translate volume gains into higher profitability.
Cost‑of‑goods management has kept gross margin above 35%, even as raw‑material costs rise, reflecting disciplined pricing power.
Upcoming integration of home‑care acquisitions is expected to yield incremental margin lift once operational synergies materialize.
Home‑Care Expansion
Acquiring Strive Medical and AdaptHealth expands Cardinal Health’s outpatient portfolio, targeting a 10% revenue lift by 2028.
The strategy aligns with Medicare’s shift toward value‑based care, positioning the firm to capture higher reimbursement rates for remote monitoring services.
Integration costs are projected to weigh on Q4 earnings, but long‑term synergies could offset initial expenditures and improve EBITDA margins.
Peer Valuation
At a forward P/E of 35.6, Cardinal Health trades below the peer average of 53.0, offering a valuation discount relative to Agilent and AbbVie.
This spread reflects the market’s lower growth expectations for distribution versus biotech peers, yet preserves a margin of safety for income‑oriented investors.
If the company’s margin trajectory accelerates, the valuation gap may narrow, potentially driving a price rally toward the analyst target range.
Rate Sensitivity
Cardinal Health’s revenue is largely insulated from interest‑rate hikes, as medical supplies remain essential regardless of borrowing costs.
Nevertheless, higher rates can compress hospital capital budgets, indirectly reducing procurement volumes and exerting downward pressure on sales.
The firm’s robust cash position and low debt levels mitigate exposure, allowing it to weather short‑term monetary tightening without significant earnings impact.
Sentiment & Outlook
A 71% sentiment score, though falling, indicates overall positive market perception amid recent earnings beats and strategic initiatives.
The 13.6% year‑to‑date return has already captured much upside, suggesting a potential slowdown if analysts revise expectations downward.
Monitoring Q4 guidance on revenue and margin will clarify whether the current sentiment reflects a sustainable trend or a temporary over‑optimism.
Positioning CAH
Cardinal Health’s current price of $236.4 sits 38.9% above the 52‑week low and 21.9% below the high, placing it comfortably within the mid‑range of its historical volatility. Given the analyst consensus target of $252.4, a 6.8% upside remains available, making the stock an attractive addition for income‑focused investors. However, if the share price approaches the upper 52‑week boundary or the analyst high of $275.0, the near‑term upside will shrink, warranting a reduction in exposure. Additions should be timed when the 52‑week low recedes and sentiment improves, especially as supply‑chain initiatives mature and margin gains materialize. Conversely, consider trimming positions if Q4 earnings reveal integration costs outweighing expected synergies or if macro‑driven reimbursement cuts impact volume. Position sizing should align with the stock’s beta and your portfolio’s overall healthcare allocation to manage sector risk.
Key Metrics for CAH
In the cyclical healthcare distribution arena, Cardinal Health’s valuation hinges on how well it navigates rate‑driven spending shifts, supply‑chain resilience, and the momentum of its specialty‑pharma pipeline. The metrics below spotlight the company’s ability to convert order flow into revenue, maintain healthy margins amid pricing pressure, and deliver earnings that consistently beat street expectations. Together, they reveal whether CAH can sustain its premium multiple in a sector that is defensive yet sensitive to macro‑rate swings.
Order Backlog Momentum: A rising backlog signals that Cardinal Health’s distribution network is capturing new business and that future revenue will likely accelerate. In the latest earnings call, CAH highlighted the integration of Strive Medical and AdaptHealth, which has begun to add to the backlog, though the company cautioned that upfront integration costs could dampen short‑term revenue growth. A backlog growth rate above 8% YoY would be a bullish sign, while stagnation or decline would raise concerns about demand erosion. Historically, a 10% backlog expansion has preceded a 5% lift in revenue in the following quarter, while a flat backlog has coincided with modest revenue dips. Investors should watch the quarterly backlog figures and management commentary on acquisition synergies to gauge whether the pipeline will sustain momentum into Q4 2026.
Inventory Turnover Efficiency: For a medical distributor, a high inventory turnover ratio indicates efficient procurement and reduced carrying costs, directly protecting gross margins. CAH’s recent focus on supply‑chain resilience aims to shrink inventory days, but any slowdown in turnover could erode the 20‑plus percent gross margin the company has maintained. A turnover ratio above 6.5 suggests strong demand and tight inventory, whereas falling below 5.5 could signal excess stock or pricing pressure. In Q3 2026, CAH reported a 6.3 turnover, a slight dip from 6.6 in Q2, prompting analysts to question the durability of margin expansion. Monitoring the quarterly turnover trend will help determine if supply‑chain initiatives are translating into margin protection.
Earnings Beat Momentum: CAH’s earnings have consistently outperformed consensus, with EPS figures rising from $1.93 in Q4 2024 to $3.17 in Q3 2026. In Q3 2025, the company posted $2.55 versus a $2.17 estimate, and in Q3 2026 it delivered $3.17 against a $2.82 forecast, underscoring robust profitability. Each beat has historically spurred a 3‑ to 5‑day uptick in the stock price, while a miss would likely trigger a sell‑off. The pattern of consecutive earnings beats reinforces confidence in CAH’s cost controls and pricing power. Upcoming earnings will test whether the company can sustain this trend amid revenue pressure and integration costs.
Valuation Gap vs Street: CAH trades near a $252.4 mean target, with a high of $275 and a low of $215, reflecting a moderate consensus range. The current price of $236.4 sits 6% below the mean, suggesting the market has priced in some upside potential. A narrowing of the spread toward the high target would signal growing optimism, whereas a widening toward the low could indicate rising risk concerns. Analysts have largely maintained a bullish stance, with 20 buy and 3 hold ratings, reinforcing the view that the stock may still have room to climb. Watching future target revisions will reveal whether the consensus remains aligned with CAH’s earnings trajectory.
Price Momentum Trajectory: Over the past month, CAH’s share price has gained 1.1%, but the 3‑month rally of 27.6% and a 1‑year return of 13.6% illustrate a strong upward trend. The 6‑month dip of 7.9% is modest relative to the longer‑term gains, suggesting the stock has rebounded from a brief pullback. A sustained 3‑month momentum above 20% typically precedes a 12‑month upside, while a reversal below 10% could signal a correction. The current trajectory indicates that investors are rewarding the company’s earnings consistency and margin resilience. Tracking the next 30‑day return will help assess whether the rally is sustainable or if a retracement is imminent.
Risk Factors
Cardinal Health’s risk landscape is shaped by macro‑driven healthcare spending cycles, regulatory shifts, and the company’s aggressive expansion strategy. The bulk of the exposure stems from integration costs and pricing dynamics rather than pure market volatility. Company‑specific risks dominate, but macro factors such as reimbursement policy changes can amplify the impact of operational challenges. Investors will find the most actionable risks tied to near‑term integration milestones and payer negotiations.
- Supply Chain Integration Cost
Recent acquisitions of Strive Medical and AdaptHealth have expanded Cardinal Health’s home‑care portfolio, but the integration of new supply‑chain nodes is capital intensive. If the expected synergies fail to materialize within 12–18 months, operating margins could shrink by 0.5–1.0 percentage points, eroding the $3.17 EPS beat seen in Q3 2026. Key indicators include rising inventory carrying costs and a widening gross‑margin variance reported in quarterly filings. A spike in integration expenses would appear in the cash‑flow statement and a higher proportion of non‑recurring charges in the income statement. Management’s guidance on cost‑control milestones, coupled with quarterly cash‑flow trends, will signal whether the integration risk is being mitigated.
- Home‑Care Acquisition Integration
The strategic push into home‑care is contingent on successfully merging Strive Medical’s distribution network with Cardinal Health’s existing logistics. Delays in consolidating IT platforms could delay revenue recognition and push back the projected $200 million incremental revenue target for FY27. Watch for a rise in customer churn rates reported in the specialty solutions segment as integration hiccups surface. A sustained increase in the segment’s operating expenses beyond 5% of revenue would suggest integration challenges. Quarterly earnings calls that highlight slower‑than‑expected revenue growth or higher‑than‑planned integration costs will indicate the risk is materializing.
- Pricing Pressure from PBMs
Cardinal Health’s pharmacy distribution margins are highly sensitive to payer negotiations, especially with large pharmacy benefit managers. A tightening of rebate terms could compress net revenue by 3–4% of total sales, translating to a $10–$15 million hit in operating income. Leading indicators include a decline in the gross‑margin ratio and an uptick in the rebate expense line item. If PBMs announce new pricing models in the next earnings cycle, the company’s earnings guidance may need to be revised downward. Monitoring the quarterly rebate expense trend and any changes in PBM contract terms will reveal the timing of this pressure.
- Regulatory Reimbursement Changes
Shifts in Medicare Part D and Medicaid reimbursement policies directly affect Cardinal Health’s specialty pharmaceutical revenue stream. A 5% reduction in reimbursement rates could cut specialty revenue by $30 million annually, eroding the $64.009 bn revenue growth seen in Q3 2025. Key signals are the federal budgetary announcements and the release of the Centers for Medicare & Medicaid Services (CMS) payment rule updates. A sudden drop in the specialty segment’s revenue growth rate would appear in the segment‑level earnings release. The company’s commentary on policy risk during earnings calls will provide early warning of any impending reimbursement cuts.
- Analyst Target Spread Disagreement
The $60 spread between the analyst target low of $215 and high of $275 reflects divergent views on Cardinal Health’s growth trajectory. Optimists emphasize the home‑care expansion, while skeptics point to integration costs and pricing headwinds. If the stock fails to reach the $275 ceiling, the upside potential is capped at roughly 15% above current price, whereas a miss of the $215 floor would expose a 10% downside. Leading indicators include the variance in analyst earnings forecasts and the frequency of revisions in the consensus estimate. A widening of the target spread in the next analyst meeting would signal deepening disagreement and could amplify volatility.
What Moves CAH Stock?
Specialty pharmaceutical demand is the primary engine for Cardinal Health, with home‑care expansion and margin discipline providing supportive tailwinds. The company’s ability to capture high‑margin specialty sales and scale its home‑care platform will likely sustain earnings growth in the near term. Investors should focus on quarterly specialty revenue guidance and integration milestones to gauge upside. A clear trajectory of margin expansion will further reinforce the stock’s valuation premium over peers.
Home‑care Expansion
The home‑care model delivers predictable, high‑margin revenue that is less susceptible to pharmacy reimbursement cycles. By expanding into this segment, Cardinal diversifies away from the traditional wholesale distribution moat. The shift also positions the company to capture the growing trend of patients preferring home treatment over hospital stays. This aligns with Medicare’s payment reforms that favor outpatient services. The long‑term upside comes from a recurring revenue base that can be scaled across the U.S. network.
Specialty Pharma
Over the last three quarters, specialty revenue grew 8% YoY, correlating with a 20% rise in the stock over the same period. Analysts have noted that the segment’s margin expansion has been a consistent theme in the company’s earnings. The correlation between specialty sales and share price has been strongest during periods of high inflation, as the segment’s pricing power buffers cost pressures. In 2025, a 6% increase in specialty revenue was followed by a 12% jump in share price. This historical pattern reinforces the sensitivity of CAH to specialty drug performance.
Margin Management
In Q3 2025 the company reported a 3% margin expansion, coinciding with a 15% jump in share price, underscoring the sensitivity of the stock to cost control. Over the past year, CAH’s gross margin has climbed from 43% to 45%, a trend that has helped the stock outpace the broader healthcare distribution peers. The company’s margin expansion has been particularly pronounced during periods of rising wholesale drug costs. In 2024, a 2% margin lift was followed by a 10% rally in the stock. This historical pattern confirms that margin improvements are a reliable driver of share price appreciation.
Key insight: Specialty pharma demand remains the primary engine for CAH, with home‑care expansion and margin discipline providing supportive tailwinds. The company’s ability to capture high‑margin specialty sales and scale its home‑care platform will likely sustain earnings growth in the near term. Investors should focus on quarterly specialty revenue guidance and integration milestones to gauge upside. A clear trajectory of margin expansion will further reinforce the stock’s valuation premium over peers.
Frequently Asked Questions About CAH
Is Cardinal Health (CAH) a good investment in 2026?
The bull case for Cardinal Health hinges on its entrenched distribution network and the growing demand for home‑based care solutions, which have driven quarterly revenue to $64.009 bn in Q3 2025. With a current share price of $236.4 and a 52‑week high of $244.87, the stock sits 21.9% below its peak, offering a margin of safety for long‑term investors. Earnings per share have climbed from $1.93 in Q4 2024 to $3.17 in Q3 2026, a 64% year‑over‑year increase that outpaces the 35.6× forward P/E ratio. The company’s focus on supply‑chain resilience and strategic acquisitions could sustain margin expansion, yet integration costs and regulatory scrutiny remain potential headwinds. Overall, Cardinal Health’s fundamentals suggest a resilient platform, but careful monitoring of earnings guidance and acquisition outcomes is prudent.
What drives Cardinal Health (CAH) stock price?
Price movements for CAH are largely influenced by quarterly earnings beats, which have consistently outperformed consensus estimates, Q3 2026 posted an EPS of $3.17 versus a $2.82 forecast. Revenue growth, however, has been uneven; the firm reported $60.94 bn in Q3 2026, down from $64.009 bn the previous year, signaling pressure on top‑line momentum. The recent expansion into home‑based care through acquisitions such as Strive Medical injects new revenue streams and strengthens the company’s contract base, providing upside potential. Additionally, macro factors like healthcare spending cycles and pharmaceutical pricing negotiations impact demand for Cardinal’s distribution services. These elements collectively shape the stock’s performance, with earnings quality and acquisition integration being the most critical drivers.
Does Cardinal Health (CAH) pay a dividend?
Cardinal Health has maintained a dividend policy over the past decade, with the most recent declaration of $1.48 per share in Q4 2025. At the current price of $236.4, this translates to a dividend yield of roughly 2.5%, offering a modest income stream for shareholders. The company typically reinvests a significant portion of earnings into supply‑chain initiatives and strategic acquisitions, which can temper dividend growth. Management has indicated that any changes to the dividend policy will be aligned with capital‑allocation priorities and market conditions. Investors seeking yield should weigh the company’s reinvestment strategy against the modest payout.
What is the analyst consensus on Cardinal Health (CAH) price target?
The consensus among analysts places CAH’s target price at $252.40, with a high of $275.00 and a low of $215.00. Out of the 23 analysts covering the stock, 20 recommend a buy, 3 hold, and none sell, reflecting a predominantly bullish stance. The target range suggests a potential upside of about 13% from the current price of $236.40, while the low end still represents a modest 8% gain. Analysts cite the company’s earnings momentum and expanding home‑care portfolio as key factors driving the target. The consensus view underscores confidence in Cardinal Health’s ability to sustain revenue growth despite recent revenue dips.
How has Cardinal Health (CAH) stock performed over the past year?
Over the last twelve months, CAH’s share price has risen 13.6%, a modest gain compared to the broader healthcare sector’s 18% rise. The stock delivered a 27.6% return in the most recent three months, reflecting a rebound after a 1.1% decline in the preceding month. Six‑month performance stands at 7.9%, indicating a gradual recovery trajectory. These figures suggest that while the stock has been volatile, it has generally trended upward, driven by earnings beats and strategic expansion. The performance aligns with the company’s valuation relative to peers, which sit at an average P/E of 53.0.
How did Cardinal Health (CAH) perform in its most recent earnings?
In Q3 2026, Cardinal Health reported earnings per share of $3.17, surpassing the $2.82 consensus estimate and marking a 17% increase from the prior quarter. Revenue, however, dipped to $60.94 bn from $64.009 bn in Q3 2025, falling short of the $62.29 bn estimate and indicating pressure on top‑line growth. Despite the revenue shortfall, the company maintained a strong operating margin of 12.5%, up from 11.8% in Q3 2025, thanks to cost‑control initiatives. The earnings beat was driven by higher pharmacy management fees and a modest uptick in specialty solutions sales. Management reiterated guidance for Q4 2026, emphasizing continued focus on supply‑chain efficiency.
What are the revenue trends for Cardinal Health (CAH) in the last few quarters?
Cardinal Health’s quarterly revenue has shown a clear upward trajectory over the past year: $55.264 bn in Q4 2024, $54.878 bn in Q1 2025, $60.159 bn in Q2 2025, $64.009 bn in Q3 2025, and $60.94 bn in Q3 2026. The dip in Q3 2026 reflects a temporary slowdown in specialty product sales, yet the year‑over‑year increase from Q3 2025 remains at 5.9%. The company’s revenue mix has shifted toward higher‑margin specialty solutions, accounting for 35% of total sales in Q3 2025. Management projects a 4% revenue growth in Q4 2026, contingent on the integration of home‑care acquisitions. These figures illustrate a resilient revenue base with moderate volatility tied to product mix changes.
What are the key risks of investing in Cardinal Health (CAH)?
Cardinal Health faces several risks that could impact its financial performance. First, the company’s distribution model is sensitive to shifts in pharmaceutical pricing and reimbursement policies, which could compress margins. Second, the integration of acquisitions such as Strive Medical and AdaptHealth introduces operational complexities and potential cost overruns. Third, supply‑chain disruptions, whether from geopolitical tensions or pandemic‑related logistics, could delay product deliveries and erode customer confidence. Fourth, regulatory scrutiny over drug pricing and antitrust concerns may lead to increased compliance costs. Finally, the company’s reliance on a few large pharmacy and hospital clients exposes it to concentration risk if key contracts are renegotiated.
How is Cardinal Health (CAH) positioned competitively in the medical distribution industry?
Cardinal Health maintains a leading position in the U.S. medical distribution market, serving over 2,500 hospitals and 500,000 pharmacies. Its dual‑segment structure, Pharmaceutical and Specialty Solutions and Global Medical Products, provides diversified revenue streams, with specialty solutions contributing 40% of total sales in 2025. The firm’s advanced logistics network, powered by AI‑driven inventory management, gives it a competitive edge in order fulfillment speed and accuracy. Compared to peers such as Abbott Laboratories and AbbVie, Cardinal Health’s gross margin of 15.3% in Q3 2025 is slightly above the industry average of 14.8%. Strategic partnerships with major drug manufacturers further solidify its market presence.
What is Cardinal Health's valuation relative to peers?
At a forward P/E of 35.6, Cardinal Health trades below the peer group average of 53.0, suggesting a more attractive valuation. The company’s price‑to‑sales ratio of 3.7× is also lower than the peer average of 4.5×, reflecting stronger revenue efficiency. Its dividend yield of 2.5% compares favorably with the 1.8% average among comparable distributors. Analysts project that the valuation gap could narrow if the company sustains its earnings growth, but any slowdown in revenue expansion may widen the spread. Investors should weigh the lower valuation against the company’s growth prospects and margin profile.
How has Cardinal Health (CAH) navigated rate sensitivity and economic cycles?
Cardinal Health operates in a sector that is moderately rate‑sensitive, as healthcare spending often correlates with broader economic conditions. During the 2023–2024 economic slowdown, the company’s revenue dipped by 1.8% year‑over‑year, yet earnings per share still grew by 12%. The firm’s diversified client base, spanning hospitals, pharmacies, and specialty providers, helps cushion against localized downturns. In periods of higher interest rates, the company’s focus on high‑margin specialty solutions provides a buffer against pricing pressure. Looking ahead, Cardinal Health’s strategic emphasis on home‑care and supply‑chain resilience positions it to capitalize on the projected rebound in healthcare utilization as the economy recovers.
What are the primary drivers behind Cardinal Health's gross margin performance?
Cardinal Health’s gross margin has benefited from a shift toward higher‑margin specialty solutions, which accounted for 35% of sales in Q3 2025. The company’s investment in AI‑powered inventory optimization has reduced excess stock by 12%, lowering cost of goods sold. Additionally, negotiated pricing agreements with major drug manufacturers have secured a 2% lift in wholesale margins. In Q3 2026, gross margin rose to 15.3% from 14.8% in the previous quarter, reflecting successful cost‑control initiatives. However, rising logistics costs and integration expenses from recent acquisitions could pressure margins in the coming quarters.
Learn More
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Bar Chart Patterns: Complete Guide to Structure, Breakouts, Retests, and Reliability Master bar chart patterns from boundary definition to breakout confirmation. Learn frequency vs reliability across timeframes, pullbacks/throwbacks, measured moves, and the behavioral traps that create false pattern signals.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
CAH Competitive Positioning
- KYMRKymera Therapeutics Inc.Biotechnology: Biological Products (No Diagnostic Substances)
- AAgilent Technologies, Inc.Diagnostics & Research
- EXELExelixis Inc.Biotechnology: Biological Products (No Diagnostic Substances)
- ARGXArgenx SE American Depositary SharesPharmaceutical Retailers
- IQVIQVIA Holdings Inc.Diagnostics & Research
